Tumor antigens bfa5 for prevention and/or treatment of cancer
WO2004066908A2
Composition containing cationic lipids and a polynucleotide or a polypeptide and method for the targeted delivery of active substances
FR2863890A1
IMMUNOSTIMULATING COMPOSITION
FR2857364A1
DOSAGE OF TECHIC ACIDS OF BACTERIA GRAM +
FR2862306A1
VACCINE COMPOSITION
EP1556082A1
Anti-cancer vaccines and high-dose cytokines as adjuvants
FR2857454A1
DOSAGE OF TECHIC ACIDS OF BACTERIA GRAM +
FR2854803A1
VACCINE COMPOSITION COMPRISING IRON PHOSPHATE AS VACCINE.
US6933137B2
Animal component free meningococcal polysaccharide fermentation and seedbank development
AU2003229429A1
Polyepitopes and mini-genes for cancer treatment
WO03085087A2
Modified cea nucleic acid and expression vectors
CA2481719A1
Modified cea nucleic acid and expression vectors
FR2851165A1
Using helix C of gp41, containing several mutations of amino acids to alanine, as antigen for generating neutralizing antibodies for treatment or prevention of human immune deficiency virus infection
US2004002455A1
Targeted immunogens
FR2850106A1
CONJUGATES OBTAINED BY REDUCTIVE AMINATION OF THE CAPSULAR POLYSACCHARIDE OF THE SEROTYPE PNEUMOCOCCUS 5
AU2002364161A1
Enhancement of the immune response using cd36-binding domain
AU2002358181A1
Mutated hiv tat
CA2462710A1
Polypeptide antigen forming a mimetic structure of the gp41 intermediate state
